---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-24-000165"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:13:58.923063+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Centessa discontinues SerpinPC, launches ORX750 Phase 2a, Q3 net loss $42.6M

## Summary
- Additional interim Phase 1 data for ORX750 in sleep-deprived volunteers showed statistically significant increase in wakefulness at all doses with favorable safety; Phase 2a initiated in NT1, NT2, IH.
- Discontinued SerpinPC development after interim analysis; net savings of ~$200M reallocated to OX2R agonist franchise.
- Cash $518.4M as of Sept 30, 2024; expected to fund operations into mid-2027.
- Completed upsized public offering in Sept 2024 resulting in net proceeds of ~$242.7M.
- Advancing ORX142 and ORX489 in IND-enabling studies; clinical data expected in 2025.

## SEC filing metadata
- accession: 0001847903-24-000165
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000165/0001847903-24-000165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000165/cnta-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-24-000165
- JSON: https://secwatch.observer/filing/0001847903-24-000165.json
- Plain text: https://secwatch.observer/filing/0001847903-24-000165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.